Abstract
Stereotactic body radiotherapy (SBRT) is increasingly becoming a key treatment option for patients with oligometastatic disease. However, a lack of randomised data limits interpretation of results from retrospective and prospective cohort studies. Whilst these studies indicate higher rates of local control with acceptable toxicity the true benefit of adding SBRT to standard therapy remains unclear. Potential therapeutic benefit may also vary between tumour sites (underlying tumour biology, natural disease course). CORE investigates whether the addition of SBRT to standard therapy improves patient outcomes in common primary tumour sites where oligometastatic disease is encountered (prostate, breast, NSCLC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
